HONG KONG – Roughly half a year after starting phase I development, Chinese biosimilars maker Bio-Thera Solutions Ltd. moved BAT-1806, its biosimilar referencing Genentech Inc.'s Roactemra (tocilizumab) for rheumatoid arthritis, into a global phase III trial.
HONG KONG – Roughly half a year after starting phase I development, Chinese biosimilars maker Bio-Thera Solutions Ltd. moved BAT-1806, its biosimilar referencing Genentech Inc.'s Roactemra (tocilizumab) for rheumatoid arthritis, into a global phase III trial.
HONG KONG – CAR T biotech Immunochina Pharmaceuticals Co. Ltd. raised ¥140 million (US$20.7 million) in a series C funding round to further develop its lead CAR T therapy targeting CD19, known as IM-19, to compete with Novartis AG's Kymriah (tisagenlecleucel).
HONG KONG – With a focus on precision drug delivery, Napajen Pharma Inc. has developed a platform technology that enables stable and selective delivery of oligonucleotide compounds to immune cells, with sights set on treating immune-related conditions, such as autoimmune diseases and cancer, as well as developing transplants and vaccines.
HONG KONG – CAR T biotech Immunochina Pharmaceuticals Co. Ltd. raised ¥140 million (US$20.7 million) in a series C funding round to further develop its lead CAR T therapy targeting CD19, known as IM-19, to compete with Novartis AG's Kymriah (tisagenlecleucel).
HONG KONG – With a focus on precision drug delivery, Napajen Pharma Inc. has developed a platform technology that enables stable and selective delivery of oligonucleotide compounds to immune cells, with sights set on treating immune-related conditions, such as autoimmune diseases and cancer, as well as developing transplants and vaccines.
HONG KONG – Founded only last year, Boston-Shanghai clinical-stage biotech startup Anji Pharmaceuticals Inc. is using its team's ties to big pharma to bring in valuable assets to be developed for indications suffered by Chinese patients, especially metabolic diseases. Most recently, it in-licensed Novartis AG's pradigastat, an inhibitor of acyl coA: diacylglycerol acyl transferase, or DGAT1, which has progressed to phase III testing in familial chylomicronemia syndrome (FCS).
HONG KONG – Founded only last year, Boston-Shanghai clinical-stage biotech startup Anji Pharmaceuticals Inc. is using its team's ties to big pharma to bring in valuable assets to be developed for indications suffered by Chinese patients, especially metabolic diseases. Most recently, it in-licensed Novartis AG's pradigastat, an inhibitor of acyl coA: diacylglycerol acyl transferase, or DGAT1, which has progressed to phase III testing in familial chylomicronemia syndrome (FCS).
HONG KONG – Looking for an immunotherapy approach against hepatitis B virus (HBV), Chinese liver disease specialist Ascletis Pharma Inc. identified a target more familiar to those working in oncology. The company licensed rights to subcutaneously administered PD-L1 antibody KN-035, developed by Suzhou Alphamab Co. Ltd., to develop for use in HBV and other viral diseases in greater China.
